|Application ||WB, IHC|
|Calculated MW||48737 Da|
|Other Names||Runt-related transcription factor 1, Acute myeloid leukemia 1 protein, Core-binding factor subunit alpha-2, CBF-alpha-2, Oncogene AML-1, Polyomavirus enhancer-binding protein 2 alpha B subunit, PEA2-alpha B, PEBP2-alpha B, SL3-3 enhancer factor 1 alpha B subunit, SL3/AKV core-binding factor alpha B subunit, RUNX1, AML1, CBFA2|
|Target/Specificity||A synthetic peptide corresponding to residues at the C-terminus of human RUNX1 was used as an immunogen.|
|Format||50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||RUNX1 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL-3 and GM-CSF promoters. The alpha subunit binds DNA and appears to have a role in the development of normal hematopoiesis. Isoform AML-1L interferes with the transactivation activity of RUNX1. Acts synergistically with ELF4 to transactivate the IL-3 promoter and with ELF2 to transactivate the mouse BLK promoter. Inhibits KAT6B- dependent transcriptional activation. Controls the anergy and suppressive function of regulatory T-cells (Treg) by associating with FOXP3. Activates the expression of IL2 and IFNG and down- regulates the expression of TNFRSF18, IL2RA and CTLA4, in conventional T-cells (PubMed:17377532).|
|Tissue Location||Expressed in all tissues examined except brain and heart. Highest levels in thymus, bone marrow and peripheral blood|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
RUNX1 (PEBP2-alpha B, Runt-related transcription factor 1, AML1) is a pivotal transcription factor essential for haematopoietic stem cell generation in the vascular regions of the aorta, vitelline and umbilical arteries, yolk sac and placenta (1). It binds DNA in cooperation with CBFbeta to activate or repress transcription, dependent upon cellular context and interaction with a variety of co-activators and co-repressors (2). RUNX1 is required for maturation of megakaryocytes and differentiation of T and B cells (3). It is one of the most frequent targets of chromosome translocations associated with leukemia (4). Mutation at the C-terminal region of RUNX1 might predict acute myeloid leukemia transformation (5).
1. Chen MJ, et al. Nature 457(7231):887-91, 2009
2. Freidman AD., et al. J Cell Physiol. 219(3):520-4, 2009
3. Ichikawa M, et al. Nat Med. 10(3):299-304, 2004
4. Zhang, Y., et al. Molec. Cell. Biol. 17: 4133-4145, 1997
5. Kuo MC., et al. Leukemia 2009
If you have any additional inquiries please email technical services at email@example.com.